Brief: Aurinia Pharmaceuticals Q3 EPS USD -0.09
02/11/2023 10:00
Nov 02 (Reuters) - Aurinia Pharmaceuticals Q3 pretax profit USD -13.149 million. * Q3 operating income USD -16.263 million * Q3 net income USD -13.447 million * Q3 product revenue USD 40.781 million
Recent news on Aurinia Pharmaceuticals
See all newsBrief: Aurinia Settles Patent Litigation With Teva
Canada's Aurinia Q2 revenue rises on LUPKYNIS sales
Brief: Aurinia Pharmaceuticals Q2 Pretax Profit USD 48.786 Million
Aurinia Pharmaceuticals Inc expected to post earnings of 24 cents a share - Earnings Preview
Brief: Lupkynis Associated With A Statistically Significant 53% Reduction In Risk Of Renal-Related Event Or Death